دسته: ایمونو هیستوشیمی

Specification:

Anti-CD45RO (T-Cell, Pan) antibody reacts with thymocytes and activated T-cells, but only on a subpopulation of resting Tcells. This antibody shows no reactivity with B-cells making it a good marker for T-cell tumours. In addition, granulocytes and monocytes are  also labelled with this antibody. T-Cell, Pan has been designated as CD45RO at The International Leukocyte Typing Workshop.

Presentation:

Mouse monoclonal antibody from supernatant diluted in tris buffered saline, pH 7.3-7.7, with protein base, and preserved with sodium azide

Specification:

ZAP-70 is a 70kDa protein tyrosine kinase found in T-cells and natural killer cells. Control of this protein translation is via the IgVH gene. In Western blotting of whole cell lysates of normal peripheral blood mononuclear cells, the antibody labels a band corresponding to ZAP-70. In Western blotting of whole cell lysates of CD19-positive purified leukemia cells from patients with lg-unmutated and lg-mutated CLL, the antibody labels a band corresponding to ZAP-70 in the Ig-unmutated CLL samples, whereas no band is observed in the Ig-mutated CLL samples. In Western blotting of cell lysates of Jurkat cells (T-lymphoblastic cell line), the antibody labels a band of 70kDa protein. In Western blotting of cell lysates of A431 cells (carcinoma cell line), no band is observed. ZAP-70 protein is expressed in leukemic cells of approximately 25% of chronic lymphocytic leukemia (CLL) cases as well. Anti-ZAP-70 expression is an excellent surrogate marker for the distinction between the g-mutated (antiZAP-70 negative) and Ig-unmutated (anti-ZAP-70 positive) CLL subtypes and can identify patient groups with divergent clinical courses. The anti-ZAP-70 positive Ig-unmutated CLL cases have been shown to have a poorer prognosis.

Immunogen:

Recombinant ZAP-70 protein including residues 1-254 and encompassing SH2 domains of human ZAP-70

Presentation:

Bioreactor Concentrate with 0.05% Azide

Specification:

Originally, the 2G9 monoclonal antibody (mAb) was described as identifying a 15 kDa protein found in the cytoplasmic granules of cytotoxic T cells that might be part of a larger 40 kDa molecule, ubiquitously expressed, named p40-TIA-1 and often referred to as TIA-1 in the literature. Now, however, there is evidence that the 2G9 mAb identifies a 17 kDa cytoplasmic granule membrane protein named GMP-17 that has no similarity with p40-TIA-1. The GMP-17 antigen is a 165 amino acid protein with 4 transmembrane domains: but it is not a typical member of the four transmembrane superfamily. It is identical with previously identified cytotoxic granule proteins called NKG7 and GIG-1 – for GCSF induced gene protein 1 –, isolated from NK cells and granulocyte-colony stimulating factor-treated mononuclear cells, respectively.  The GMP-17 protein is also found in the granules of CD14+ monocytes and neutrophils. Conversely, GMP-17 is not expressed in B lymphocytes or B-cell lines. In humans, NKG7, the GMP-17 gene, is localized on chromosome 19q13-33. As the target cell-induced NK cell degranulation results in translocation of GMP-17 from granules to the plasma membrane, a possible role for GMP-17 in the formation of junctions between effector cells and target cells has been suggested. Furthermore, sequence homology with calcium channel proteins has suggested that it may regulate ion channels required for cytotoxic effector functions. The 2G9 mAb was evaluated during the 5th HLDA Workshop on Human Leucocyte Differentiation Antigens, in the section of monoclonal antibodies reactive with intracellular antigens.

Immunogen:

Human bone marrow malignant cells from a non- B, non-T acute leukemia

Presentation:

Liquid purified Ascites, purified with Protein G Chromatography with 15mM Sodium Azide

Specification:

Recognizes a single glycoprotein of 520kDa, identified as mucin 2 (MUC2). This MAb shows no cross-reaction with human milk fat globule membranes, MUC1, or MUC3. Mucins are high molecular weight glycoproteins, which constitute the major component of the mucus layer that protects the gastric epithelium. MUC2 is specifically expressed in goblet cells of the small intestine & colon; in about 65% of colonic carcinomas and about 40% of gastric carcinomas. MUC2 is rarely expressed outside of the GI tract with the exceptions of mucinous carcinoma of breast and clear cell-type carcinomas of the ovary.

Immunogen:

A synthetic peptide of 29 amino acids, KYPTTTPISTTTMVTPTPTPTGTQTPTTT from MUC2 protein, coupled to KLH

Presentation:

200ug/ml of Ab purified from Bioreactor Concentrate by Protein A/G. Prepared in 10mM PBS with 0.05% BSA & 0.05% azide

Specification:

Membrane receptor signaling by various ligands, including interferons and growth hormones such as EGF, induces activation of JAK kinases which then leads to tyrosine phosphorylation of proteins that have been designated Stats (signal transducers and activators of transcription). The first members of this family to be described include Stat1α p91, Stat1β p84 (a form of p91 that lacks 38 COOH-terminal amino acids) and Stat2 p113. Stat1 and Stat2 are induced by IFN-α and form a heterodimer which is part of the ISGF-3 transcription factor complex. Stat3, which becomes activated in response to epidermal growth factor (EGF) and interleukin-6 (IL-6), but not interferon-γ (IFN-γ) or Stat4, is an additional member of this family. It has been suggested that the phosphorylated forms of both Stat3 and Stat4 form homodimers as well as heterodimers with the other members of the Stat family, and that differential activation of different Stat proteins in response to different ligands should help to explain specificity in nuclear signaling from the cell surface. Highest expression of Stat4 is seen in testis and myeloid cells. IL-12 has been identified as an activator of Stat4. Other members of the Stat family include Stat5, which has been shown to be activated by Prolactin and by IL-3, and Stat6 (also designated IL-4 Stat), which is involved in IL-4-activated signaling pathways.

Presentation:

Antibody in PBS Buffer, with less than 0.1% sodium azide and 0.1% gelatin

Specification:

MSH2 is a mismatch repair gene which is deficient in a high proportion of patients with microsatellite instability (MSI-H). This finding is associated with the autosomal dominant condition known as Hereditary Non-Polyposis Colon Cancer (HNPCC). The anti-MSH2 antibody is useful in screening patients and families for this condition. Colon cancers that are microsatellite unstable have a better prognosis than their microsatellite stable counterparts.

Presentation:

MSH2 (G219-1129) primary antibody in Tris Buffer, pH 7.3-7.7, with 1% BSA and <0.1% Sodium Azide